COLUMBIA, Md. - Marylandian -- Precision Antibody, a leader in custom monoclonal antibody development, announces its participation in the Targeted Therapies Licensing & Partnering Summit Asia 2026, taking place February 26–27, 2026, in Meguro-ku, Tokyo, Japan.

Precision Antibody will attend the partnering-focused meeting alongside A&G Pharmaceutical, Inc., engaging with biopharmaceutical companies, investors, and research leaders to explore strategic collaborations in targeted therapies and antibody-based drug development.

The Targeted Therapies Licensing & Partnering Summit Asia is a premier event designed to facilitate high-value business development discussions, licensing opportunities, and cross-border partnerships within oncology and precision medicine. The summit provides a dedicated platform for companies advancing innovative therapeutic assets to connect with potential partners across Asia and globally.

More on Marylandian

• RecallSentry™ App Launch — Your Home Safety Hub — Free on iOS & Android
• Award-Winning Director Crystal J. Huang's Under-$50K Film "The Ritual House" Wins Best Horror Feature at Golden State Film Festival
• Grads aren't getting hired — here's what we're doing about it
• K2 Integrity Enhances Technology Capabilities Through Acquisition of Leviathan Security Group
• #WeAreGreekWarriors Comes to Detroit in Celebration of Women's History Month

Precision Antibody brings to the meeting its extensive expertise in custom monoclonal antibody development, including fully human antibody generation and biomarker-focused antibody solutions that support therapeutic and translational research initiatives.

"Partnering meetings like this play a critical role in accelerating innovation," said Dr. Serrero. "We look forward to engaging with potential collaborators in Tokyo and exploring opportunities to advance targeted therapy programs through strategic partnerships."

As biomarker antibody specialists, Precision Antibody has established a strong track record in developing high-quality, high-affinity monoclonal antibodies for oncology research. The company is also a proud contributor to the National Cancer Institute's Clinical Proteomic Technologies for Cancer (CPTC) program through Leidos, helping establish gold-standard monoclonal antibodies widely used in cancer biomarker research.

More on Marylandian

• Natalie Jean Channels Strength Through Softness on New Album Unbreakable Spirit
• Maryland: NEWS RELEASE: Time to CHOW down and Celebrate-Chesapeake Oyster Week March 20-31
• Energywise Solutions and Pickleball Pros Partner to Bring More Energy and Visibility to Pickleball Clubs
• Buildout Launches CRM, Completing the Industry's First AI-Powered End-to-End Deal Engine for CRE
• The Franchise King® Releases Free Guide for Nervous Buyers

Through its collaboration-driven approach and commitment to scientific excellence, Precision Antibody continues to support biopharma partners in accelerating the discovery and development of next-generation targeted therapeutics.

Attendees of the Targeted Therapies Licensing & Partnering Summit Asia 2026 are invited to connect with representatives from Precision Antibody and A&G Pharmaceutical to discuss licensing opportunities, co-development partnerships, and strategic collaborations.

Event Details:

Targeted Therapies Licensing & Partnering Summit Asia 2026
Dates: February 26–27, 2026
Location: Meguro-ku, Tokyo, Japan
Event Website: https://targeted-therapies-asia.com/